Detalhe da pesquisa
1.
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Int J Cancer
; 153(6): 1300-1312, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37260183
2.
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.
Cancer Immunol Immunother
; 71(8): 1823-1835, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984538
3.
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Int J Mol Sci
; 23(20)2022 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36293498
4.
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
Cancer Immunol Immunother
; 70(6): 1691-1704, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388994
5.
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.
Genet Med
; 23(4): 698-704, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33442023
6.
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Mod Pathol
; 33(12): 2580-2590, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32616874
7.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Int J Cancer
; 145(7): 1970-1981, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30807643
8.
Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.
J Natl Compr Canc Netw
; 16(4): 352-358, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29632054
9.
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.
Cancers (Basel)
; 16(9)2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730712
10.
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
Clin Genitourin Cancer
; 22(3): 102047, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430859
11.
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis.
Clin Transl Oncol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421563
12.
Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution.
Clin Transl Oncol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722534
13.
Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment.
Diagnostics (Basel)
; 13(13)2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37443615
14.
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
Clin Genitourin Cancer
; 21(3): e166-e174, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36610891
15.
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Clin Genitourin Cancer
; 20(1): 25-34, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34789409
16.
Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy.
Biomedicines
; 9(9)2021 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34572311
17.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Front Oncol
; 10: 1677, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33014837
18.
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer.
Oncotarget
; 9(19): 15061-15067, 2018 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29599926
19.
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
JAMA Oncol
; 2(6): 744-50, 2016 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26940233
20.
BRAF inhibitors in metastatic non-small cell lung cancer.
J Thorac Dis
; 10(2): 589-592, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29607117